Justin Chakma
Chief Business Officer · ARS Pharmaceuticals, Inc.
- 2024
- Nov 14, 2025
- 6
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Justin Chakma files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Eric Karas - $250K in SPRY purchases and sales in the last 12 months
- Brian Dorsey - $190K in SPRY purchases and sales in the last 12 months
- Alexander A. Fitzpatrick - $34K in SPRY purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Justin Chakma?
Justin Chakma is a corporate insider, tracked as Chief Business Officer of ARS Pharmaceuticals, Inc. (SPRY). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Justin Chakma last file a Form 4?
The most recent primary Form 4 on record is dated 14 November 2025, one of 6 filings going back to 2024.
Has Justin Chakma been buying or selling stock?
Recorded transactions: 0 open-market purchases and 13 open-market sales ($8.56M) across all tracked filings.
